Dr. Priyom Bose

Feature Writer

B.Sc. Botany, M.Sc. Plant Biology and Biotechnology, Ph.D. Plant Biology and Biotechnology

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.

Articles from Priyom

Effectiveness of COVID-19 vaccines in New York State

A new study reports that BNT162b2 booster doses are safe and have shown enhancement in short-term protection against the Delta variant.

3 Dec 2021

Systematic survey of human SARS-CoV-2 monoclonal antibodies

Scientists have mined information from several research publications and patents to create a dataset of approximately 8000 human antibodies to the SARS-CoV-2 spike from more than 200 donors.

2 Dec 2021

Study suggests efficacy of SARS-CoV-2 main protease inhibitors is not compromised in current COVID-19 variants

A new study has focussed on assessing the Mpro mutants of newly emerged SARS-CoV-2 variants.

2 Dec 2021

COVID-19 vaccination status based infection likelihood in New Zealand

A new study has determined the possible number of infections caused by an unvaccinated versus vaccinated individual.

1 Dec 2021

Comparison of peptides from human cardiac proteins and SARS-CoV-2 proteins

A new study investigated whether linear peptides contained in proteins (primarily expressed in the heart) also occur in the SARS-CoV-2 proteome.

1 Dec 2021

Study compares NAbs from natural SARS-CoV-2 infection vs. vaccine induced against symptomatic infection

Scientists have recently compared the levels of antibody concentrations in unvaccinated, SARS-CoV-2 convalescent individuals and COVID-19 specific antibodies in vaccinated individuals.

30 Nov 2021

An antiviral regimen based on biomimetic polymers for COVID-19

In a new study published on the bioRxiv* preprint server, scientists proposed the aforementioned mechanism of action (MOA) and have validated it using electron photomicrographs of murine cytomegalovirus (MCMV), which were incubated with a nanoviricide.

30 Nov 2021

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

In a recent study, published on the bioRxiv* preprint server, researchers identified human LRRC15 as an inhibitory receptor for SARS-CoV-2 entry, which directly binds to the receptor-binding domain (RBD) of the spike protein with a moderate affinity and inhibits spike-mediated entry.

29 Nov 2021

SARS-CoV-2 Delta spike increases viral virulence and inflammatory cytokine production

In a new study published on the bioRxiv* preprint server, scientists investigated several virological features of the Delta spike protein.

29 Nov 2021

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

In a new study, published on the bioRxiv* preprint server, scientists aimed to determine the reaction of the molnupiravir parent drug (NHC) to different SARS-CoV-2 Variants of Concern (VoCs). They also sought to establish the therapeutic window in a human lung cell model.

29 Nov 2021

Dr. Priyom Bose

Articles from Priyom

Effectiveness of COVID-19 vaccines in New York State

Systematic survey of human SARS-CoV-2 monoclonal antibodies

Study suggests efficacy of SARS-CoV-2 main protease inhibitors is not compromised in current COVID-19 variants

COVID-19 vaccination status based infection likelihood in New Zealand

Comparison of peptides from human cardiac proteins and SARS-CoV-2 proteins

Study compares NAbs from natural SARS-CoV-2 infection vs. vaccine induced against symptomatic infection

An antiviral regimen based on biomimetic polymers for COVID-19

Human LRRC15 protein is an inhibitory receptor for SARS-CoV-2 spike-mediated entry

SARS-CoV-2 Delta spike increases viral virulence and inflammatory cytokine production

Study on molnupiravir precursor NHC antiviral activity against SARS-CoV-2 variants of concern

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News